ArticleCureus2026
Anti-phospholipase A2 Receptor Membranous Nephropathy Presenting as Common Geriatric Complaints: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-phospholipase A2 receptor (anti-PLA2R) antibodies are an established cause of primary membranous nephropathy (MN). However, typical symptoms of proteinuria, such as peripheral oedema and frothy urine, are not easily identified in the elderly, and other non-specific presentations, such as hypoglycaemia and fluid overload, may lead to delays in diagnosis. We report a case of anti-PLA2R-associated MN in an elderly woman who presented with fluid overload and recurrent hypoglycaemia, both of which are common in this age group. Renal function and anti-PLA2R antibody titres improved substantially following treatment with rituximab. This case underscores the importance of early clinical suspicion and timely intervention in elderly patients in order to preserve residual renal function and optimise outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.